Fusidic acid – topicalClassification: B
Drug products: Fucidin, Fucidin®, Fucidin®-Hydrocortison, Fucidine, Fucidin-Hydrocortison, Fucithalmic, Fucithalmic®, Fusidinsyra/Betametason Ebb, Fusidinsyra/Betametason LEO, Fusidinsyra/Hydrokortison 2care4
ATC code: D06AX01, D07CA01, D07CC01, S01AA13
Published controlled studies on differences between men and women on efficacy, safety and pharmacokinetics for topical fusidic acid are lacking.
Pharmacokinetics and dosing
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of topical fusidic acid have been found.
No studies with a clinically relevant sex analysis regarding the effects of topical fusidic acid have been found.
No studies with a clinically relevant sex analysis regarding adverse effects of topical fusidic acid have been found.
Reproductive health issues
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
A retrospective analysis of patients with eczema or psoriasis on standard dermatological treatment (295 men, 291 women) found that significantly more men than women (79; 63%, 47; 37%) were administered whole-body UV treatment. Also, the results indicated that men had more treatments appointments per individual than women. Women were prescribed more emollients than men .
Date of litterature search: 2022-06-29
Reviewed by: Diana Rydberg
Approved by: Karin Schenck-Gustafsson